Search
Natamycin
go.drugbank.com/drugs/DB00826ApprovedInvestigationalIt is used for a variety of fungal infections, mainly topically. [PubChem]
International brands: N-MycinPiroxicam
go.drugbank.com/drugs/DB00554ApprovedInvestigationalA cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea … Its long half-life enables it to be administered once daily.
Synonyms: 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxidCefadroxil
go.drugbank.com/drugs/DB01140ApprovedInvestigationalVet approvedWithdrawnLong-acting, broad-spectrum, water-soluble, cephalexin derivative.
EDP1815
go.drugbank.com/drugs/DB16486InvestigationalEDP1815, was investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions
CCR5 mAb
go.drugbank.com/drugs/DB05906ExperimentalIt was generated by HGS using the Abgenix XenoMouse technology. … CCR5 mAb is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor CCR5, which is known to be a key facilitator of infection with human immunodeficiency virus (
GW 468816
go.drugbank.com/drugs/DB05417InvestigationalGW 468816 is glycine receptor antagonist. It is designed to aid abstinence in people who have just quit smoking, delaying the time to relapse. It was undergoing phase II trials since December 2003.
Categories: Receptors, N-Methyl-D-Aspartate, antagonists & inhibitorsAVI-4020
go.drugbank.com/drugs/DB05873InvestigationalAVI-4020 is a neugene antisense drug candidate for the treatment of patients with acute West Nile virus disease who have serious neurological impairment (WNV neuroinvasive disease).
CPD 923
go.drugbank.com/drugs/DB05856ExperimentalCPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.